CHF supports the effective, safe and successful entry of biosimilars into the Australian market. This is in the interest of consumers as they will have access to a wider group of therapeutic options. In line with the National Medicines Policy safe and effective medicines should be available to consumers at the lowest possible cost. Patients should not have to pay more for a biosimilar than a reference brand.